Quest Clinical Research

San Francisco, California 94115-3029

3 studies enrolling now · 87 studies all time

What they study most

Acquired Immunodeficiency Syndrome, Cancer, Cardiovascular Disease, Chronic HBV Infection, Chronic Hepatitis, Chronic Hepatitis B, Chronic Hepatitis C, Chronic Hepatitis D Infection, Cytomegalovirus Retinitis, Dyslipidemia, Genital Herpes Simplex Type 2, HIV

Studies at this site

• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) — Recruiting now
• HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study — Running, not enrolling
• A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) — Running, not enrolling
• A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) — Running, not enrolling
• Study of GS-3242 in Participants With HIV-1; Substudy-05 — Completed
• Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors — Completed
• A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection — Stopped early
• A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors — Enrolling by invitation
• Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) — Completed
• An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study — Stopped early
• TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals — Completed
• Study of GS-1219 in Participants With HIV-1 — Stopped early
• Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients — Running, not enrolling
• Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients — Running, not enrolling
• Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC — Stopped early
• A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) — Completed
• Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART — Completed
• Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment — Stopped early
• Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101 — Enrolling by invitation
• Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T — Stopped early
• A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection — Stopped early
• A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients — Stopped early
• Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection — Completed
• A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors — Stopped early
• A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection — Stopped early
• Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) — Stopped early
• Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis — Stopped early
• A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2) — Completed
• Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants — Completed
• Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T — Completed
• A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection — Completed
• A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV) — Completed
• A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B — Completed
• Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) — Completed
• Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection — Completed
• Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH — Completed
• Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection — Completed
• Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV — Completed
• A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis — Completed
• Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects — Completed
• Bococizumab HIV Evaluation (B-HIVE) Study — Stopped early
• Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C) — Completed
• Gilead Sustained Virologic Response (SVR) Registry — Completed
• Evaluating New Formulation of Therapeutic HSV-2 Vaccine — Completed
• A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response — Completed
• A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV) — Completed
• Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity — Completed
• Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine — Completed
• Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study — Completed
• Study of SCY-635, Pegasys and Copegus in Hepatitis C — Completed